Amyloidosis Hereditary Transthyretin Related

2

Review clinical trials related to Amyloidosis Hereditary Transthyretin Related. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Participants needed: 250
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eidos Therapeutics, a BridgeBio companyUpdated: Aug 11, 2025
Eligibility criteria

Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only,... [+7]

Status: Recruiting

Exercise in Hereditary ATTR (ATTRv) Amyloidosis

This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare genetic disease caused by mutations in the transthyretin gene, leading to the deposition of amyloid fibrils in nerves and organs.

Participants needed: 42
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of MaiaUpdated: Jun 24, 2025Locations: 1
Eligibility criteria

ATTRv Amyloidosis patients living in Portugal; [+3]